Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Wells Fargo upgrades Tandem Diabetes to Overweight, raises target to $160 » 06:40
01/19/22
01/19
06:40
01/19/22
06:40
TNDM

TNDM

/

+

, MDT

Medtronic

$107.52 /

-1.02 (-0.94%)

, PODD

Insulet

$234.33 /

-8.45 (-3.48%)

As previously reported,…

As previously reported, Wells Fargo analyst Lawrence Biegelsen upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with a price target of $160, up from $137. The analyst sees multiple sources of potential upside to Street estimates over the next few years. Namely, Biegelsen believes delays to Medtronic's (MDT) 780G and Insulet's (PODD) Omnipod 5 could drive upside to sales in 2022. In addition, he sees upside potential to his outside the U.S. sales in 2022, given that this will be the first full year when Tandem's Control IQ will be available in France and Germany. Lastly, Tandem should benefit from a strong renewal cycle starting in 2022, the analyst adds.

ShowHide Related Items >><<
TNDM TNDM
/

+

PODD Insulet
$234.33 /

-8.45 (-3.48%)

MDT Medtronic
$107.52 /

-1.02 (-0.94%)

TNDM TNDM
/

+

01/19/22 Wells Fargo
Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
12/20/21 Piper Sandler
Tandem Diabetes price target raised to $170 from $150 at Piper Sandler
12/15/21 Piper Sandler
Tandem likely main beneficiary of Medtronic's FDA warning, says Piper Sandler
MDT Medtronic
$107.52 /

-1.02 (-0.94%)

01/19/22 Wells Fargo
Wells Fargo upgrades DexCom to Overweight with $575 price target
01/10/22 Piper Sandler
Piper will give Medtronic 'benefit of the doubt' on Affera, still cautious
01/10/22 BTIG
Medtronic downgraded to Neutral from Buy at BTIG
01/07/22 Morgan Stanley
Medtronic downgraded to Equal Weight at Morgan Stanley amid pipeline delays
PODD Insulet
$234.33 /

-8.45 (-3.48%)

01/03/22 William Blair
Insulet nearing 'positive growth inflection,' says William Blair
12/06/21 Canaccord
Insulet Omnipod 5 delay not a game changer, says Canaccord
12/05/21 Citi
Insulet delayed Omnipod 5 launch again, says Citi
TNDM TNDM
/

+

PODD Insulet
$234.33 /

-8.45 (-3.48%)

MDT Medtronic
$107.52 /

-1.02 (-0.94%)

MDT Medtronic
$107.52 /

-1.02 (-0.94%)

TNDM TNDM
/

+

MDT Medtronic
$107.52 /

-1.02 (-0.94%)

MDT Medtronic
$107.52 /

-1.02 (-0.94%)

Upgrade
Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo » 05:24
01/19/22
01/19
05:24
01/19/22
05:24
TNDM

TNDM

/

+

Wells Fargo analyst…

Wells Fargo analyst Lawrence Biegelsen upgraded Tandem Diabetes to Overweight from Equal Weight with a $160 price target.

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
12/20/21 Piper Sandler
Tandem Diabetes price target raised to $170 from $150 at Piper Sandler
12/15/21 Piper Sandler
Tandem likely main beneficiary of Medtronic's FDA warning, says Piper Sandler
12/07/21 Lake Street
Tandem Diabetes price target raised to $200 from $165 at Lake Street
TNDM TNDM
/

+

TNDM TNDM
/

+

Over a week ago
Recommendations
Lake Street names 18 small cap best ideas for 2022 » 09:03
12/28/21
12/28
09:03
12/28/21
09:03
ACHV

Achieve Life Sciences

$8.14 /

+0.245 (+3.10%)

, APEN

Apollo Endosurgery

$7.89 /

+0.08 (+1.02%)

, ATCX

Atlas Technical Consultants

$8.19 /

+0.22 (+2.76%)

, PMTS

CPI Card Group

$19.93 /

+0.23 (+1.17%)

, DMTK

DermTech

$16.28 /

-1.64 (-9.15%)

, DHX

DHI Group

$6.24 /

+0.21 (+3.48%)

, HYRE

HyreCar

$4.62 /

-0.25 (-5.13%)

, ICAD

iCAD

$7.11 /

-0.155 (-2.13%)

, INVE

Identiv

$28.30 /

+3.9 (+15.98%)

, LMB

Limbach Holding

$8.97 /

-0.06 (-0.66%)

, MBII

Marrone Bio

/

+

, PIII

P3 Health Partners

$7.55 /

+0.25 (+3.42%)

, PERI

Perion Network

$24.78 /

+0.88 (+3.68%)

, SPWH

Sportsman's Warehouse

$11.52 /

+0.025 (+0.22%)

, SSYS

Stratasys

$24.34 /

+0.43 (+1.80%)

, STKL

SunOpta

$6.90 /

+0.1 (+1.47%)

, TNDM

TNDM

/

+

, MVEN

Arena Group

/

+

Lake Street's ten…

Lake Street's ten senior research analysts have selected their 18 small cap best ideas for 2022, calling these "ideas to give small cap PMs a leg up in their search for alpha." The list, which all have Buy ratings at the firm, includes Achieve Life Sciences (ACHV), Apollo Endosurgery (APEN), Atlas Technical Consultants (ATCX), CPI Card Group (PMTS), DermTech (DMTK), DHI Group (DHX), HyreCar (HYRE), iCAD (ICAD), Identiv (INVE), Limbach Holding (LMB), Marrone Bio (MBII), P3 Health Partners (PIII), Perion Network (PERI), Sportsman's Warehouse (SPWH), Stratasys (SSYS), SunOpta (STKL), Tandem Diabetes (TNDM) and Arena Group (MVEN).

ShowHide Related Items >><<
TNDM TNDM
/

+

STKL SunOpta
$6.90 /

+0.1 (+1.47%)

SSYS Stratasys
$24.34 /

+0.43 (+1.80%)

SPWH Sportsman's Warehouse
$11.52 /

+0.025 (+0.22%)

PMTS CPI Card Group
$19.93 /

+0.23 (+1.17%)

PERI Perion Network
$24.78 /

+0.88 (+3.68%)

MVEN Arena Group
/

+

MBII Marrone Bio
/

+

LMB Limbach Holding
$8.97 /

-0.06 (-0.66%)

INVE Identiv
$28.30 /

+3.9 (+15.98%)

ICAD iCAD
$7.11 /

-0.155 (-2.13%)

HYRE HyreCar
$4.62 /

-0.25 (-5.13%)

DMTK DermTech
$16.28 /

-1.64 (-9.15%)

DHX DHI Group
$6.24 /

+0.21 (+3.48%)

ATCX Atlas Technical Consultants
$8.19 /

+0.22 (+2.76%)

APEN Apollo Endosurgery
$7.89 /

+0.08 (+1.02%)

ACHV Achieve Life Sciences
$8.14 /

+0.245 (+3.10%)

ACHV Achieve Life Sciences
$8.14 /

+0.245 (+3.10%)

10/04/21
Fly Intel: Top five analyst initiations
10/04/21 Alliance Global Partners
Achieve Life Sciences initiated with a Buy at Alliance Global Partners
07/22/21 Lake Street
NIH grant opens new opportunity for Achieve's cytisinicline, says Lake Street
07/20/21 Lake Street
Achieve Life weakness on Chantix news would be opportunity, says Lake Street
APEN Apollo Endosurgery
$7.89 /

+0.08 (+1.02%)

12/15/21 Cowen
Apollo Endosurgery initiated with an Outperform at Cowen
12/09/21 Stifel
Apollo Endosurgery initiated with a Buy at Stifel
10/04/21 Piper Sandler
Apollo Endosurgery remains 'underappreciated small-cap' name, says Piper Sandler
09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
ATCX Atlas Technical Consultants
$8.19 /

+0.22 (+2.76%)

11/19/21 Stifel
Stifel calls Atlas 'most underappreciated infrastructure stimulus play'
09/21/21 Johnson Rice
Atlas Technical Consultants initiated with a Buy at Johnson Rice
08/17/21 Lake Street
Atlas Technical Consultants price target raised to $18 from $15 at Lake Street
08/12/21 Stifel
Stifel remains 'very positive' on Atlas Technical Consultants outlook
PMTS CPI Card Group
$19.93 /

+0.23 (+1.17%)

12/16/21 Lake Street
CPI Card Group initiated with a Buy at Lake Street
DMTK DermTech
$16.28 /

-1.64 (-9.15%)

11/21/21 BTIG
DermTech price target lowered to $48 from $53 at BTIG
11/10/21 Craig-Hallum
DermTech price target lowered to $50 from $70 at Craig-Hallum
10/14/21 Cowen
DermTech coverage transferred at Cowen
05/03/21
Fly Intel: Top five analyst initiations
DHX DHI Group
$6.24 /

+0.21 (+3.48%)

12/20/21 Lake Street
DHI Group management meetings increase confidence at Lake Street
11/30/21 Lake Street
DHI Group initiated with a Buy at Lake Street
09/09/21 B. Riley
DHI Group price target raised to $6 from $5.75 at B. Riley
08/06/21 B. Riley
DHI Group price target raised to $5.75 from $5 at B. Riley
HYRE HyreCar
$4.62 /

-0.25 (-5.13%)

11/10/21 Ladenburg
Ladenburg upgrades HyreCar to Buy on valuation after selloff
11/10/21 Ladenburg
HyreCar upgraded to Buy from Neutral at Ladenburg
08/11/21
Fly Intel: Top five analyst downgrades
08/11/21 DA Davidson
HyreCar price target lowered to $22 from $25 at DA Davidson
ICAD iCAD
$7.11 /

-0.155 (-2.13%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
INVE Identiv
$28.30 /

+3.9 (+15.98%)

12/01/21 B. Riley
Identiv shares not fully pricing in prescription pill program, says B. Riley
11/03/21 B. Riley
Identiv price target raised to $31 from $26 at B. Riley
09/28/21 Lake Street
Identiv price target raised to $24 from $20 at Lake Street
09/20/21 B. Riley
Identiv price target raised to $26 from $22 at B. Riley
LMB Limbach Holding
$8.97 /

-0.06 (-0.66%)

08/13/21 Lake Street
Limbach Holding price target raised to $21 from $19 at Lake Street
03/05/21
Fly Intel: Top five analyst initiations
03/05/21 Lake Street
Limbach Holding initiated with a Buy at Lake Street
MBII Marrone Bio
/

+

09/22/21 Roth Capital
Marrone Bio initiated with a Buy at Roth Capital
05/14/21 Lake Street
Marrone Bio weakness a buying opportunity, says Lake Street
03/24/21 H.C. Wainwright
Marrone Bio price target raised to $4 from $2.50 at H.C. Wainwright
02/19/21 Canaccord
Marrone Bio price target raised to $3.50 from $2 at Canaccord
PIII P3 Health Partners
$7.55 /

+0.25 (+3.42%)

PERI Perion Network
$24.78 /

+0.88 (+3.68%)

12/13/21 Raymond James
Perion Network initiated with an Outperform at Raymond James
10/26/21 Roth Capital
Perion Network price target raised to $43 from $40 at Roth Capital
10/26/21 Oppenheimer
Oppenheimer ups Perion target to $35, sees 'favorable backdrop' in Q4
10/26/21 Oppenheimer
Perion Network price target raised to $35 from $30 at Oppenheimer
SPWH Sportsman's Warehouse
$11.52 /

+0.025 (+0.22%)

12/06/21 Lake Street
Sportsman's Warehouse upgraded to Buy from Hold at Lake Street
12/03/21 Craig-Hallum
Sportsman's Warehouse upgraded to Buy from Hold at Craig-Hallum
01/07/21 Credit Suisse
Sportsman's Warehouse downgraded to Neutral from Outperform at Credit Suisse
SSYS Stratasys
$24.34 /

+0.43 (+1.80%)

11/08/21 Loop Capital
Stratasys price target raised to $35 from $19 at Loop Capital
11/04/21 Craig-Hallum
Craig-Hallum raises Stratasys price target to $46 following quarterly results
11/04/21 JPMorgan
Stratasys downgraded to Underweight at JPMorgan after 'outsized move'
11/04/21 JPMorgan
Stratasys downgraded to Underweight from Neutral at JPMorgan
STKL SunOpta
$6.90 /

+0.1 (+1.47%)

11/11/21 Canaccord
SunOpta price target lowered to $15 from $20 at Canaccord
09/10/21 Cowen
Cowen starts SunOpta at Outperform with $15 price target
09/10/21 Cowen
SunOpta initiated with an Outperform at Cowen
08/11/21 Lake Street
Lake Street remains bullish on SunOpta following quarterly results
TNDM TNDM
/

+

12/20/21 Piper Sandler
Tandem Diabetes price target raised to $170 from $150 at Piper Sandler
12/15/21 Piper Sandler
Tandem likely main beneficiary of Medtronic's FDA warning, says Piper Sandler
12/07/21 Lake Street
Tandem Diabetes price target raised to $200 from $165 at Lake Street
12/06/21 Piper Sandler
Tandem Diabetes price target raised to $150 from $140 at Piper Sandler
MVEN Arena Group
/

+

11/22/21 Lake Street
Arena Group re-initiated with a Buy at Lake Street
TNDM TNDM
/

+

STKL SunOpta
$6.90 /

+0.1 (+1.47%)

SSYS Stratasys
$24.34 /

+0.43 (+1.80%)

SPWH Sportsman's Warehouse
$11.52 /

+0.025 (+0.22%)

PERI Perion Network
$24.78 /

+0.88 (+3.68%)

MBII Marrone Bio
/

+

LMB Limbach Holding
$8.97 /

-0.06 (-0.66%)

INVE Identiv
$28.30 /

+3.9 (+15.98%)

ICAD iCAD
$7.11 /

-0.155 (-2.13%)

HYRE HyreCar
$4.62 /

-0.25 (-5.13%)

DMTK DermTech
$16.28 /

-1.64 (-9.15%)

DHX DHI Group
$6.24 /

+0.21 (+3.48%)

ATCX Atlas Technical Consultants
$8.19 /

+0.22 (+2.76%)

APEN Apollo Endosurgery
$7.89 /

+0.08 (+1.02%)

  • 09
    Dec
  • 13
    Oct
  • 25
    May
  • 08
    Apr
  • 03
    Mar
  • 03
    Mar
  • 11
    Feb
  • 04
    Feb
  • 20
    Jan
  • 07
    Jan
MVEN Arena Group
/

+

ICAD iCAD
$7.11 /

-0.155 (-2.13%)

ATCX Atlas Technical Consultants
$8.19 /

+0.22 (+2.76%)

TNDM TNDM
/

+

SPWH Sportsman's Warehouse
$11.52 /

+0.025 (+0.22%)

PERI Perion Network
$24.78 /

+0.88 (+3.68%)

HYRE HyreCar
$4.62 /

-0.25 (-5.13%)

DMTK DermTech
$16.28 /

-1.64 (-9.15%)

ATCX Atlas Technical Consultants
$8.19 /

+0.22 (+2.76%)

APEN Apollo Endosurgery
$7.89 /

+0.08 (+1.02%)

STKL SunOpta
$6.90 /

+0.1 (+1.47%)

SPWH Sportsman's Warehouse
$11.52 /

+0.025 (+0.22%)

PERI Perion Network
$24.78 /

+0.88 (+3.68%)

LMB Limbach Holding
$8.97 /

-0.06 (-0.66%)

HYRE HyreCar
$4.62 /

-0.25 (-5.13%)

ACHV Achieve Life Sciences
$8.14 /

+0.245 (+3.10%)

Over a month ago
Recommendations
Tandem Diabetes price target raised to $170 from $150 at Piper Sandler » 04:50
12/20/21
12/20
04:50
12/20/21
04:50
TNDM

TNDM

/

+

, MDT

Medtronic

$100.64 /

-1.56 (-1.53%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on Tandem Diabetes (TNDM) to $170 from $150 and keeps an Overweight rating on the shares after hosting a meeting with management. Following Medtronic's (MDT) warning letter last week, Tandem expects as many as 80,000-90,000 Medtronic patients, or as much as $360M in potential sales, will be up for renewal in the next year, O'Brien tells investors in a research note. The company is highly confident in its ability to handle any excess demand it should see, adds the analyst. O'Brien left the meeting "incrementally more bullish" on Tandem's pipeline and its ability to deliver on numbers.

ShowHide Related Items >><<
TNDM TNDM
/

+

MDT Medtronic
$100.64 /

-1.56 (-1.53%)

TNDM TNDM
/

+

12/15/21 Piper Sandler
Tandem likely main beneficiary of Medtronic's FDA warning, says Piper Sandler
12/07/21 Lake Street
Tandem Diabetes price target raised to $200 from $165 at Lake Street
12/06/21 Piper Sandler
Tandem Diabetes price target raised to $150 from $140 at Piper Sandler
12/06/21 Piper Sandler
Tandem new tubeless kit should ease some concerns, says Piper Sandler
MDT Medtronic
$100.64 /

-1.56 (-1.53%)

12/17/21
Fly Intel: Top five analyst downgrades
12/17/21 Oppenheimer
Medtronic price target lowered to $136 from $145 at Oppenheimer
12/17/21 BTIG
Medtronic price target lowered to $128 from $138 at BTIG
12/17/21 JPMorgan
Medtronic downgraded to Neutral on pipeline setbacks at JPMorgan
TNDM TNDM
/

+

MDT Medtronic
$100.64 /

-1.56 (-1.53%)

MDT Medtronic
$100.64 /

-1.56 (-1.53%)

TNDM TNDM
/

+

MDT Medtronic
$100.64 /

-1.56 (-1.53%)

MDT Medtronic
$100.64 /

-1.56 (-1.53%)

Conference/Events
Tandem Diabetes management to meet virtually with Piper Sandler » 04:55
12/17/21
12/17
04:55
12/17/21
04:55
TNDM

TNDM

/

+

Virtual Meeting to be…

Virtual Meeting to be held on December 17 hosted by Piper Sandler.

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

12/15/21 Piper Sandler
Tandem likely main beneficiary of Medtronic's FDA warning, says Piper Sandler
12/07/21 Lake Street
Tandem Diabetes price target raised to $200 from $165 at Lake Street
12/06/21 Piper Sandler
Tandem Diabetes price target raised to $150 from $140 at Piper Sandler
12/06/21 Piper Sandler
Tandem new tubeless kit should ease some concerns, says Piper Sandler
TNDM TNDM
/

+

TNDM TNDM
/

+

Recommendations
Tandem likely main beneficiary of Medtronic's FDA warning, says Piper Sandler » 11:34
12/15/21
12/15
11:34
12/15/21
11:34
MDT

Medtronic

$104.10 /

-7.58 (-6.79%)

, TNDM

TNDM

/

+

, PODD

Insulet

$271.73 /

+16.88 (+6.62%)

After Medtronic (MDT)…

After Medtronic (MDT) announced that it received a warning letter from the FDA suggesting that specific quality checks were inadequately met after inspections of its diabetes headquarters in July and lowered its diabetes segment guidance for Q3 and FY22, Piper Sandler analyst Matt O'Brien said he thinks Tandem Diabetes (TNDM) will likely be the "primary beneficiary" of Medtronic's lost revenues through calendar 2022, though Insulet (PODD) may see some benefit as well. While the news "is certainly less than positive" for Medtronic, and he continues to think the company's diabetes franchise will remain a laggard for at least a couple more years, O'Brien likes other key drivers in the business, leading him to reiterate his Overweight rating on Medtronic, on which he has a $152 price target.

ShowHide Related Items >><<
TNDM TNDM
/

+

PODD Insulet
$271.73 /

+16.88 (+6.62%)

MDT Medtronic
$104.10 /

-7.58 (-6.79%)

MDT Medtronic
$104.10 /

-7.58 (-6.79%)

12/15/21 Stifel
Medtronic price target raised to $140 from $138 at Stifel
12/15/21 Citi
Citi cuts Medtronic target, removes from Focus List
12/09/21 RBC Capital
RBC starts Medtronic at Outperform, says pipeline 'underappreciated'
12/09/21 RBC Capital
Medtronic initiated with an Outperform at RBC Capital
TNDM TNDM
/

+

12/07/21 Lake Street
Tandem Diabetes price target raised to $200 from $165 at Lake Street
12/06/21 Piper Sandler
Tandem Diabetes price target raised to $150 from $140 at Piper Sandler
12/06/21 Piper Sandler
Tandem new tubeless kit should ease some concerns, says Piper Sandler
12/05/21 Citi
Insulet delayed Omnipod 5 launch again, says Citi
PODD Insulet
$271.73 /

+16.88 (+6.62%)

12/06/21 Canaccord
Insulet Omnipod 5 delay not a game changer, says Canaccord
11/05/21 Canaccord
Insulet price target raised to $330 from $300 at Canaccord
11/05/21 Citi
Insulet price target raised to $350 from $325 at Citi
TNDM TNDM
/

+

PODD Insulet
$271.73 /

+16.88 (+6.62%)

MDT Medtronic
$104.10 /

-7.58 (-6.79%)

MDT Medtronic
$104.10 /

-7.58 (-6.79%)

TNDM TNDM
/

+

MDT Medtronic
$104.10 /

-7.58 (-6.79%)

MDT Medtronic
$104.10 /

-7.58 (-6.79%)

Conference/Events
Tandem Diabetes management to meet virtually with Piper Sandler » 11:48
12/13/21
12/13
11:48
12/13/21
11:48
TNDM

TNDM

/

+

Virtual Meeting to be…

Virtual Meeting to be held on December 17 hosted by Piper Sandler.

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

12/07/21 Lake Street
Tandem Diabetes price target raised to $200 from $165 at Lake Street
12/06/21 Piper Sandler
Tandem Diabetes price target raised to $150 from $140 at Piper Sandler
12/06/21 Piper Sandler
Tandem new tubeless kit should ease some concerns, says Piper Sandler
12/05/21 Citi
Insulet delayed Omnipod 5 launch again, says Citi
TNDM TNDM
/

+

TNDM TNDM
/

+

Recommendations
Tandem Diabetes price target raised to $200 from $165 at Lake Street » 08:43
12/07/21
12/07
08:43
12/07/21
08:43
TNDM

TNDM

/

+

Lake Street analyst…

Lake Street analyst Brooks O'Neil raised the firm's price target on Tandem Diabetes to $200 from $165 and keeps a Buy rating on the shares following the company's investor day meeting, which he said "offered a glimpse into their product pipeline" and "suggested a much broader vision than we expected." Tandem already has "by far" the best durable pump on the market today and its family of new pumps to be delivered over the next several years includes a next generation durable pump along with two new form factor pumps that will offer small size, phone control, and a variety of infusion sets as well as a new patch pump with a very discrete form factor. He expects Tandem to continue to deliver strong results in both the short and longer-term, added O'Neil.

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

12/06/21 Piper Sandler
Tandem Diabetes price target raised to $150 from $140 at Piper Sandler
12/06/21 Piper Sandler
Tandem new tubeless kit should ease some concerns, says Piper Sandler
12/05/21 Citi
Insulet delayed Omnipod 5 launch again, says Citi
11/04/21 Raymond James
Tandem Diabetes price target raised to $138 from $120 at Raymond James
TNDM TNDM
/

+

TNDM TNDM
/

+

Recommendations
Tandem Diabetes price target raised to $150 from $140 at Piper Sandler » 19:44
12/06/21
12/06
19:44
12/06/21
19:44
TNDM

TNDM

/

+

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on Tandem Diabetes to $150 from $140 and keeps an Overweight rating on the shares after the company's R&D day where it provided an update on several new pipleine products as well as some near-term and longer-term financial targets. The new disclosure were a "net positive", and he sees the management's 2022 sales growth guidance of over 20% as "sustainable going forward", the analyst tells investors in a research note.

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

12/06/21 Piper Sandler
Tandem new tubeless kit should ease some concerns, says Piper Sandler
12/05/21 Citi
Insulet delayed Omnipod 5 launch again, says Citi
11/04/21 Raymond James
Tandem Diabetes price target raised to $138 from $120 at Raymond James
11/04/21 Wells Fargo
Tandem Diabetes price target raised to $137 from $121 at Wells Fargo
TNDM TNDM
/

+

TNDM TNDM
/

+

Recommendations
Tandem new tubeless kit should ease some concerns, says Piper Sandler » 14:51
12/06/21
12/06
14:51
12/06/21
14:51
TNDM

TNDM

/

+

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien notes that Tandem Diabetes has announced that it will be introducing both a tubeless kit for its Mobi pump as well as a disposable patch pump. The tubeless features and ability to be sold through the pharmacy should help address areas of the business that have historically been criticized by some investors, the analyst contends. Consequently, O'Brien anticipates it will ease some of these concerns and eventually will allow Tandem to remain a dominant player in the pump market going forward. The analyst is unsure of the exact timing of these products, but the company committed to launching them in the 5-year forecasting window by 2027. He has an Overweight rating and a price target of $140 on the shares.

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

12/05/21 Citi
Insulet delayed Omnipod 5 launch again, says Citi
11/04/21 Raymond James
Tandem Diabetes price target raised to $138 from $120 at Raymond James
11/04/21 Wells Fargo
Tandem Diabetes price target raised to $137 from $121 at Wells Fargo
11/04/21 Piper Sandler
Tandem Diabetes price target raised to $140 from $132 at Piper Sandler
TNDM TNDM
/

+

TNDM TNDM
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.